A two-year clinical lifestyle intervention program for weight loss in obesity

Food and Nutrition Research

Volumn 52, Issue , 2008, Pages

  Andersson, Karin ^a   Karlström, Brita ^a   Fredén, Susanne ^a   Petersson, Helena ^a   Öhrvall, Margareta ^a   Zethelius, Björn ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Food intake; Overweight; Physical activity; Sagital abdominal diameter; Triglycerides; Weight changes

Indexed keywords

EID: 77952503492     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v52i0.1656     Document Type: Article

References (33)

1. WHO (1997): Obesity: preventing and managing the global epidemic. WHO Technical Report Series, No. 894. Geneva: World Health Organisation.
2. Persson U, Ö degard K. Indirekta kostnader till fö ljd av sjukdomar relaterade till övervikt och fetma. IHE, e-report 2003:5, pp 1-20, www.ihe.se.
3. SBU. Obesity a grave epidemic. The Swedish council on technology assessment in health care (2002) report number 160, pp 401-59, www.sbu.se. ISBN: 91-87890-78-X.
4. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 280-8.
5. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2002; 106: 453-8. (Pubitemid 30666377)
6. Isomaa B, Almgren P, Tuomi T, Forsen B, Lathi K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9. (Pubitemid 32893993)
7. Depres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-9.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-53. (Pubitemid 28319935)
9. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
10. Zavaroni I, Bonini L, Gasparani P, Barilli AL, Zuccarelli A, Dall'Aglio E, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism 1999; 48: 989-94. (Pubitemid 29374916)
11. McLaughlin TL, Reaven GM. Beyond type 2 diabetes: the need for a clinical useful way to identify insulin resistance (Editorial). Am J Med 2003; 114: 501-2. (Pubitemid 36515114)
12. Riserius U, Ärnlöv J, Brismar K, Zethelius B, Berglund L, Vessby B. Sagital abdominal diameter is a strong anthropometric marker of insulin resistance and hyperproinsulinemia in obese men. Diabetes Care 2004; 27: 2042-6.
13. .Ö hrvall M, Berglund L, Vessby B. Sagital abdominal diameter compared with other anthropometric measurements in relation to cardiovascular risk. Int J Obes 2000; 24: 497-501.
14. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
15. Toumiletho J, Lindström J, Eriksson J, Valle T, Hämiläinen H, Ilanne-Parrika P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subject with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50. (Pubitemid 32378388)
16. Knowler WC, Barret-Connor E, Fowler SE, Hamman RF, Lachin JM,Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention and metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
17. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397-415.
18. Svenska Livsmedelsverket (Swedish National Food Administration). Svenska näringsrekommendationer (Swedish dietary recommendations) [In Swedish]. Vår föda 1997; 2: 8-14.
19. Karlström B, Vessby B, Eliasson M. Diet - a balanced approach, 1989. Diabetes 1988. Proceedings of the 13th Congress of the International Diabetes Federation, Sydney, 20-25 November 1988.
20. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-72. (Pubitemid 28327800)
21. Andersson I, Rössner S. Weight development, dropout pattern and changes in obesity-related risk factors after two years of treatment of obese men. Int J Obes 1997; 21: 211-6. (Pubitemid 27117034)
22. Sjö ström CD, Lissner L, Sjö ström L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res 1997; 5: 119-30.
23. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537-44.
24. Eriksson KF, Lindgarde F. Prevention of type 2 (NID) diabetes mellitus by diet and physical exercise: the 6-year Malmöfeasibility study. Diabetologia 1991; 34: 891-8.
25. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
26. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-9.
27. Berglund L, Lithell H. Prediction models for insulin resistance. Blood Press 1996; 5: 274-7. (Pubitemid 26290690)
28. Hokansson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of HDL cholesterol level: a meta analysis of population based prospective studies. J Cardiovasc Risk 1996; 2: 213-9. (Pubitemid 26266496)
29. Kahn HS, Simoes EJ, Koponen R. The abdominal diameter index and sudden coronary death in men. Am J Cardiol 1996; 78: 961-4. (Pubitemid 126658666)
30. Seidel JC, Andres R, Sorkin JD, Muller DC. The sagital waist diameter and mortality in men: the Baltimore Longitudinal Study on Ageing. Int J Obes 1994; 18: 61-7. (Pubitemid 24029247)
31. Foreyt JP, Goodrick GK. Factors common to successful therapy for obese patients. Med Sci Sports Exerc 1991; 23: 292-7.
32. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al.; for the STORM Study Group M. Predictors of weight loss and maintenance during 2 years of treatment of subutramine in obesity. Results from the European multi-centre STORM-trial. Int J Obes Relat Metab Disord 2001; 25: 496-501. (Pubitemid 32289643)
33. Melin I, Reynisdottir, Berglund L, Zamfir M, Karlström B. Motivating clinical treatment of obesity, methods, education, supervision and outcome. Thesis, paper No. 4, Karolinska University Hospital Huddinge, Stockholm, 2004.